Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Reiser

Showing results (211-220 of 242) with videos related to

Pageof 25
Sort By:
Biorxiv : the Preprint Server for Biology|August 30, 2024
CD11b suppresses TLR7-driven inflammatory signaling to protect against lupus nephritisXiaobo Li, Veronica Villanueva, Viviana Jimenez, et al.
Nature Medicine|May 12, 2015
Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal modelsMario Schiffer, Beina Teng, Changkyu Gu, et al.
The Journal of Clinical Investigation|February 8, 2019
uPAR isoform 2 forms a dimer and induces severe kidney disease in miceChangli Wei, Jing Li, Brian D Adair, et al.
Kidney International|March 14, 2018
Single-nephron proteomes connect morphology and function in proteinuric kidney diseaseMartin Höhne, Christian K Frese, Florian Grahammer, et al.
JAMA Pediatrics|September 6, 2017
Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in ChildrenFranz Schaefer, Howard Trachtman, Elke Wühl, et al.
The New England Journal of Medicine|January 30, 2020
Soluble Urokinase Receptor and Acute Kidney InjurySalim S Hayek, David E Leaf, Ayman Samman Tahhan, et al.
Journal of the American Heart Association|December 10, 2021
Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19Michael Pan, Alexi Vasbinder, Elizabeth Anderson, et al.
Journal for Immunotherapy of Cancer|July 11, 2023
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancerSachin R Jhawar, Shang-Jui Wang, Aditya Thandoni, et al.
The Journal of Clinical Investigation|September 14, 2011
CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survivalSuma Yaddanapudi, Mehmet M Altintas, Andreas D Kistler, et al.
Nature Medicine|August 2, 2011
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosisChangli Wei, Shafic El Hindi, Jing Li, et al.
Pageof 25

Showing results (211-220 of 242) with videos related to

Sort By:
Pageof 25
Biorxiv : the Preprint Server for Biology|August 30, 2024
CD11b suppresses TLR7-driven inflammatory signaling to protect against lupus nephritisXiaobo Li, Veronica Villanueva, Viviana Jimenez, et al.
Nature Medicine|May 12, 2015
Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal modelsMario Schiffer, Beina Teng, Changkyu Gu, et al.
The Journal of Clinical Investigation|February 8, 2019
uPAR isoform 2 forms a dimer and induces severe kidney disease in miceChangli Wei, Jing Li, Brian D Adair, et al.
Kidney International|March 14, 2018
Single-nephron proteomes connect morphology and function in proteinuric kidney diseaseMartin Höhne, Christian K Frese, Florian Grahammer, et al.
JAMA Pediatrics|September 6, 2017
Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in ChildrenFranz Schaefer, Howard Trachtman, Elke Wühl, et al.
The New England Journal of Medicine|January 30, 2020
Soluble Urokinase Receptor and Acute Kidney InjurySalim S Hayek, David E Leaf, Ayman Samman Tahhan, et al.
Journal of the American Heart Association|December 10, 2021
Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19Michael Pan, Alexi Vasbinder, Elizabeth Anderson, et al.
Journal for Immunotherapy of Cancer|July 11, 2023
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancerSachin R Jhawar, Shang-Jui Wang, Aditya Thandoni, et al.
The Journal of Clinical Investigation|September 14, 2011
CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survivalSuma Yaddanapudi, Mehmet M Altintas, Andreas D Kistler, et al.
Nature Medicine|August 2, 2011
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosisChangli Wei, Shafic El Hindi, Jing Li, et al.
Pageof 25